Clinical Trial Update: Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the efficacy, tolerability, and safety of once-daily atomoxetine hydrochloride versus placebo in Russian children and adolescents w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Atomoxetine hydrochloride (Atomoxetine hydrochloride)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED